Overview

This text-based CME activity provides guidance and expert recommendations on the initial diagnostic workup and therapy selection, as well as an overview of the latest data on recently approved and emerging therapeutic options for patients with B-cell non-Hodgkin lymphoma (NHL). Although recent treatment advances do not provide a cure, they do, however, provide longer remissions and improve patient outcomes. We invite you to learn more about the current standard of care, recently approved treatment options, including PI3K inhibitors, as well as safety and efficacy data from the select clinical trials.

Content Areas

Presentation and workup

Advancing the treatment paradigm

PI3K pathway inhibitors

Other select new therapy strategies for B-cell NHL

This activity is supported by an independent educational grant from Bayer.

CE/CME STATEMENT

Target Audience

This activity was developed for hematologists/oncologists, hematologists, medical oncologists and other healthcare providers who care for patients with Non-Hodgkin Lymphoma (NHL).

Learning Objectives

At the conclusion of this activity, participants should be better able to:

Apply NCCN practice guidelines, expert recommendations, and/or the outcomes of clinical trials to select the optimal treatment for patients with indolent or aggressive NHL throughout the course of the disease

Evaluate the clinical efficacy and safety data from trials of PI3K inhibitors

Faculty Reviewer

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of
1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Constantin A. Dasanu, MD, PhD

No significant relationships to disclose

The faculty reviewer for this activity has disclosed that there will be
no
discussion about the use of products for non-FDA approved indications.

Additional Content Planners

Annenberg Center for Health Sciences

Charles Willis, Director, Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by an independent educational grant from Bayer.

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is
1.00 hour.

This activity was originally released on
September 07, 2018 and is eligible for credit through
September 06, 2019.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/